clinical trial · NCT04004507
Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances
Ocuphire Pharma, Inc.·phase2·completed·n = 24
Decrease in Night VisionDisturbance; Vision, LossPhentolamine Mesylate Ophthalmic Solution 1%Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
brief summary
The objectives of this study are: * To assess the effect of ophthalmic phentolamine mesylate in mesopic conditions on the four endpoints: 1. Contrast sensitivity 2. Low contrast visual acuity 3. Wavefront aberrometry 4. Subjective questionnaire * To assess the safety of ophthalmic phentolamine mesylate
started
Aug 1, 2007
primary completion
Oct 1, 2007
completion
Feb 1, 2008
last updated
Feb 15, 2024
detailed description
Double-masked, placebo-controlled, single-dose Phase 2 study in 24 patients experiencing severe night vision difficulties to evaluate ocular and systemic safety and efficacy following administration of one drop of phentolamine mesylate 1.0% QD in each eye for 1 day.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol